The FDA has granted orphan drug designation (ODD) to LP-284, a next-generation acylfulvene small molecule, for the treatment ...
Sixth overall for Lantern’s A.I.-driven precision oncology pipelineOrphan designation expands LP-284's potential for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback